LL-37
Also known as: Cathelicidin, CAP18
Popular For
Antimicrobial, infections, biofilm disruption, wound healing
Key Facts: LL-37
- Category
- Immune
- FDA Status
- Not FDA Approved
- Clinical Status
- Investigational - Clinical trials for wound healing
- Administration
- Subcutaneous injection or topical
- Typical Dose
- 100-200 mcg daily
- Frequency
- Once daily
- Evidence Level
- Human Trials
- Duration
- Variable by protocol
Mechanism of Action
LL-37 directly kills bacteria, fungi, and some viruses by disrupting their cell membranes. It also modulates the immune response, promotes wound healing, reduces inflammation, and has anti-biofilm activity against bacterial infections.
Research Summary
Research demonstrates broad antimicrobial activity including against antibiotic-resistant bacteria. Studies show wound healing benefits, anti-biofilm effects, and immune modulation. Being investigated for chronic infections and wound healing applications.
Dosing Information
Typical Dosingⓘ
Community experience
100-200 mcg daily
50-300 mcg daily
Once daily
Antimicrobial peptide. Used for infections, biofilm disruption. Some use higher doses for acute infections.
Research Dosingⓘ
Scientific studies
Doses from research protocols
Doses from Studies
100-200 mcg subcutaneous
Varies by indication
Duration
Variable by protocol
Administration
Subcutaneous injection or topical
Timing & Administration
Best Time to Take
Morning
As directed, typically once daily
Food Recommendation
With or without food
Why This Timing?
LL-37 is an antimicrobial peptide. Morning use supports daytime immune surveillance.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Injection site reactions (common)
- ●Skin toxicity (ulcers, burning)
- ●Allergic reactions
- ●May trigger histamine release - use caution with MCAS or histamine sensitivity
- ●May contribute to autoimmune conditions
- ●High-dose toxicity concerns
- ●Limited long-term safety data
References
Related Peptides
Peptides commonly compared with LL-37 or used in similar applications.
Thymosin Alpha-1
Clinical TrialsA naturally occurring thymic peptide that enhances immune function. Approved in over 35 countries for hepatitis B/C and as an immune adjuvant.
ImmuneKPV
PreclinicalA tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.
ImmuneVIP
Clinical TrialsA naturally occurring peptide with immunomodulatory and anti-inflammatory effects. Being studied for ARDS, pulmonary hypertension, and autoimmune conditions.
ImmuneThymogen
Clinical TrialsA synthetic dipeptide (Glu-Trp) bioregulator derived from Thymalin, a thymus extract. One of Professor Khavinson's key immunomodulatory peptides, shown to stimulate T-lymphocyte development and normalize immune function. Has been used clinically in Russia for immune support.
ImmuneEnfuvirtide
FDAA peptide HIV fusion inhibitor that blocks viral entry into cells. First approved drug in the fusion inhibitor class.
ImmunePNC27
PreclinicalA chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. Selectively kills cancer cells by binding to HDM-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected.
ImmuneLooking for a trusted vendor?
Pro members get access to verified vendors with quality standards & exclusive discount codes.
Want updates on LL-37 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.